An emerging role of PARK2 in cancer

Journal of Molecular Medicine

Volumn 92, Issue 1, 2014, Pages 31-42

  Xu, Liang ^a   Lin, De Chen ^a,b   Yin, Dong ^c   Koeffler, H Phillip ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Deletion; Metabolism; Mitophagy; Mutation; PARK2; Tumor suppressor

Indexed keywords

MESSENGER RNA; PARKIN; PROTEIN TYROSINE KINASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL METABOLISM; COPY NUMBER VARIATION; DNA METHYLATION; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME STRUCTURE; GENE MUTATION; HOMEOSTASIS; HUMAN; MICROTUBULE; MITOCHONDRIAL GENOME; MITOCHONDRION; MITOPHAGY; NEOPLASM; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84891888589     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1107-0     Document Type: Review

References (130)

1. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305 (Pubitemid 30437317)
2. Wenzel DM, Lissounov A, Brzovic PS, Klevit RE (2011) UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 474:105-108
3. Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, Schneider DS, Nakamura K, Shiloh MU, Cox JS (2013) The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 501:512-516
4. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608 (Pubitemid 28207717)
5. Mira MT, Alcais A, Van Thuc N, Moraes MO, Di Flumeri C, Thai VH, Phuong MC, Huong NT, Ba NN, Khoa PX et al (2004) Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427:636-640 (Pubitemid 38248483)
6. Ali S, Vollaard AM, Widjaja S, Surjadi C, van de Vosse E, van Dissel JT (2006) PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin Exp Immunol 144:425-431 (Pubitemid 43799925)
7. Alcalay RN, Clark LN, Marder KS, Bradley WE (2012) Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer 51:1109-1113
8. Sun XD, Liu M, Hao JH, Li DW, Luo YG, Wang XC, Yang YF, Li F, Shui WQ, Chen Q et al (2013) Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle 12:1133-1141
9. Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, Ang AX, Yip DL, Sung JX, Tan PH, Bay BH et al (2010) Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem 285:29231-29238
10. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo FJ, Cantley LC, Wyllie AH, Adams DJ et al (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 107:15145-15150
11. Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK, Koh LW, Foong CS, Sandanaraj E, Holbrook JD et al (2012) Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 72:2543-2553
12. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W et al (2010) Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42:77-82
13. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schule B, Klein C, Shridhar V, Roberts LR et al (2004) Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40:85-96 (Pubitemid 38579877)
14. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR et al (2004) Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10:2720-2724 (Pubitemid 38509147)
15. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Mascillo V et al (2003) Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 100:5956-5961 (Pubitemid 36581860)
16. West AB, Kapatos G, O'Farrell C, Gonzalez-de-Chavez F, Chiu K, Farrer MJ, Maidment NT (2004) N-myc regulates parkin expression. J Biol Chem 279:28896-28902 (Pubitemid 38915757)
17. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, Hu W, Feng Z (2011) Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A 108:16259-16264
18. Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, Galehdar Z, Palmisano V, Patenge N, Berg D et al (2011) Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 18:769-782
19. Klinkenberg M, Gispert S, Dominguez-Bautista JA, Braun I, Auburger G, Jendrach M (2012) Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics 13:9-21
20. Wang HQ, Imai Y, Kataoka A, Takahashi R (2007) Cell type-specific upregulation of parkin in response to ER stress. Antioxid Redox Signal 9:533-542 (Pubitemid 46598251)
21. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A, Noguchi A, Springer D, Bocharov AV, Eggerman TL et al (2011) Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest 121:3701-3712
22. Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, Chiba T (2009) Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced parkin in human colorectal cancers. International journal of cancer Journal international du cancer 125:2029-2035
23. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C et al (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14:459-468
24. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C et al (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15:1488-1497
25. Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 7(Suppl 1):S12 11-14
26. Fallon L, Moreau F, Croft BG, Labib N, Gu WJ, Fon EA (2002) Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem 277:486-491 (Pubitemid 34952083)
27. Trempe JF, Sauve V, Grenier K, Seirafi M, Tang MY, Menade M, Al-Abdul-Wahid S, Krett J, Wong K, Kozlov G et al (2013) Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340:1451-1455
28. Riley BE, Lougheed JC, Callaway K, Velasquez M, Brecht E, Nguyen L, Shaler T, Walker D, Yang Y, Regnstrom K et al (2013) Structure and function of parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun 4:1982
29. Spratt DE, Martinez-Torres RJ, Noh YJ, Mercier P, Manczyk N, Barber KR, Aguirre JD, Burchell L, Purkiss A, Walden H et al (2013) A molecular explanation for the recessive nature of parkin-linked Parkinson's disease. Nat Commun 4:1983
30. Chaugule VK, Burchell L, Barber KR, Sidhu A, Leslie SJ, Shaw GS, Walden H (2011) Autoregulation of parkin activity through its ubiquitin-like domain. Embo J 30:2853-2867
31. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ (2013) PINK1 drives parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 200:163-172
32. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 107:16691-16696
33. Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci 31:157-163
34. Avraham E, Rott R, Liani E, Szargel R, Engelender S (2007) Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 282:12842-12850 (Pubitemid 47100582)
35. Yamamoto A, Friedlein A, Imai Y, Takahashi R, Kahle PJ, Haass C (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280:3390-3399 (Pubitemid 40223802)
36. Rubio de la Torre E, Luzon-Toro B, Forte-Lago I, Minguez-Castellanos A, Ferrer I, Hilfiker S (2009) Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet 18:809-823
37. Trempe JF, Chen CX, Grenier K, Camacho EM, Kozlov G, McPherson PS, Gehring K, Fon EA (2009) SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol Cell 36:1034-1047
38. Walden H, Martinez-Torres RJ (2012) Regulation of parkin E3 ubiquitin ligase activity. Cell Mol Life Sci 69:3053-3067
39. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404
40. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1
41. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB (2008) Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10:634-642 (Pubitemid 351883879)
42. Gu JA, Ajani JA, Hawk ET, Ye YQ, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu XF (2010) Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res 3:1176-1186
43. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu GT, Kato M et al (2009) High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 7:665-677
44. Iwakawa R, Okayama H, Kohno T, Sato-Otsubo A, Ogawa S, Yokota J (2012) Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma. Genes Chromosomes Cancer 51:462-472
45. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684
46. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao YJ, Turashvili G, Ding JR, Tse K, Haffari G et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-399
47. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ et al (2006) Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118:1945-1953
48. Toma MI, Wuttig D, Kaiser S, Herr A, Weber T, Zastrow S, Koch R, Meinhardt M, Baretton GB, Wirth MP et al (2013) PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome. Genes Chromosomes Cancer 52:265-273
49. Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI (2003) Alterations in the common fragile site gene parkin in ovarian and other cancers. Oncogene 22:8370-8378 (Pubitemid 37485529)
50. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adelaide J, Geneix J, Xerri L, Dubreuil P et al (2007) Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 26:298-307 (Pubitemid 46095741)
51. Wang HX, Liu BB, Zhang C, Peng GY, Liu M, Li DW, Gu F, Chen Q, Dong JT, Fu L et al (2009) Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. Journal of Pathology 218:76-85
52. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Gene Chromosome Canc 38:40-52 (Pubitemid 36994883)
53. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L et al (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277-2291 (Pubitemid 37160872)
54. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628-43635 (Pubitemid 37345989)
55. von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A 101:10744-10749 (Pubitemid 38955813)
56. Perez FA, Palmiter RD (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 102:2174-2179 (Pubitemid 40262031)
57. Sato S, Chiba T, Nishiyama S, Kakiuchi T, Tsukada H, Hatano T, Fukuda T, Yasoshima Y, Kai N, Kobayashi K et al (2006) Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J Neurosci Res 84:1350-1357 (Pubitemid 44654458)
58. Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, Soda M, Nakimawa K, Kiyama H, Stern DM, Hori O et al (2007) Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16:50-60 (Pubitemid 46152544)
59. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H (2007) Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 16:2377-2393 (Pubitemid 47514484)
60. Stephenson SEM, Taylor JM, Lockhart PJ (2012) Parkinson's disease and parkin: insights from Park2 knockout mice. In: Dushanova J (ed). Mechanisms in Parkinson's disease - models and treatments InTech.
61. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R, Chiba T (2008) Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27:6002-6011
62. Cookson MR (2012) Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb Perspect Med 2:a009415
63. Narendra D, Walker JE, Youle R (2012) Mitochondrial quality control mediated by PINK1 and parkin: links to parkinsonism. Cold Spring Harb Perspect Biol. doi: 10.1101/cshperspect.a011338
64. Ashrafi G, Schwarz TL (2013) The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ 20:31-42
65. Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 100:15077-15082 (Pubitemid 37518019)
66. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y et al (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. The Journal of clinical investigation 112:1809-1820 (Pubitemid 38063704)
67. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N (2011) Autophagy-deficient mice develop multiple liver tumors. Gene Dev 25:795-800
68. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J (2005) Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 280:17154-17162 (Pubitemid 41389181)
69. Ren Y, Jiang H, Yang F, Nakaso K, Feng J (2009) Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem 284:4009-4017
70. Ren Y, Zhao J, Feng J (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23:3316-3324 (Pubitemid 36531973)
71. Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, Mizuno Y, Dawson TM, Dawson VL (2005) Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 14:71-84 (Pubitemid 40123464)
72. Olzmann JA, Li L, Chudaev MV, Chen J, Perez FA, Palmiter RD, Chin LS (2007) Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 178:1025-1038 (Pubitemid 47443324)
73. Kaverina I, Straube A (2011) Regulation of cell migration by dynamic microtubules. Semin Cell Dev Biol 22:968-974
74. Watanabe T, Noritake J, Kaibuchi K (2005) Regulation of microtubules in cell migration. Trends Cell Biol 15:76-83 (Pubitemid 40188217)
75. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A (2003) Parkin is a component of an SCF-like ubipuitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37:735-749 (Pubitemid 36288547)
76. Jiang Q, Ren Y, Feng J (2008) Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J Neurosci 28:12993-13002
77. Zhao J, Ren Y, Jiang Q, Feng J (2003) Parkin is recruited to the centrosome in response to inhibition of proteasomes. J Cell Sci 116:4011-4019 (Pubitemid 37279315)
78. Chen Y, Fang ST, Yeh PC, Yang HH, Chen SY, Chang CJ, Zhai WJ, Chen YC, Juang YL (2012) The C-terminus of PARK2 is required for its self-interaction, solubility and role in the spindle assembly checkpoint. Biochim Biophys Acta 1822:573-580
79. Liu M, Aneja R, Sun X, Xie S, Wang H, Wu X, Dong JT, Li M, Joshi HC, Zhou J (2008) Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem 283:35783-35788
80. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H, Matsumoto T (2006) Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15:883-895 (Pubitemid 43338230)
81. Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Miesel F, Sharma M, Bornemann A, Berg D, Gasser T et al (2009) Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18:3832-3850
82. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144:689-702
83. Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ (2010) Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A 107:11835-11840
84. Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer. Oncogene 25:4647-4662 (Pubitemid 44187615)
85. Chatterjee A, Mambo E, Sidransky D (2006) Mitochondrial DNA mutations in human cancer. Oncogene 25:4663-4674 (Pubitemid 44187616)
86. Zanssen S, Schon EA (2005) Mitochondrial DNA mutations in cancer. PLoS Med 2:e401 (Pubitemid 41735771)
87. Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, Kimura M, Go E, Koyano F, Funayama M et al (2012) PINK1 autophosphorylation upon membrane potential dissipation is essential for parkin recruitment to damaged mitochondria. Nat Commun 3:1016
88. Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon EA (2012) Mitochondrial processing peptidase regulates PINK1 processing, import and parkin recruitment. EMBO Rep 13:378-385
89. Lazarou M, Jin SM, Kane LA, Youle RJ (2012) Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase parkin. Dev Cell 22:320-333
90. Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M et al (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2:120080
91. Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, Hattori N (2012) PINK1-mediated phosphorylation of the parkin ubiquitin-like domain primes mitochondrial translocation of parkin and regulates mitophagy. Sci Rep 2:1002
92. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP, Harper JW (2013) Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496:372-376
93. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, Hess S, Chan DC (2011) Broad activation of the ubiquitin-proteasome system by parkin is critical for mitophagy. Hum Mol Genet 20:1726-1737
94. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147:893-906
95. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology 183:795-803
96. Van Humbeeck C, Cornelissen T, Hofkens H, Mandemakers W, Gevaert K, De Strooper B, Vandenberghe W (2011) Parkin interacts with Ambra1 to induce mitophagy. J Neurosci 31:10249-10261
97. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W (2010) PINK1/parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12:119-131
98. Narendra D, Kane LA, Hauser DN, Fearnley IM, Youle RJ (2010) p62/SQSTM1 is required for parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 6:1090-1106
99. Gogvadze V, Orrenius S, Zhivotovsky B (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18:165-173
100. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614-18622 (Pubitemid 38623283)
101. Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ (2009) Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 18:4317-4328
102. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M et al (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12:517-526 (Pubitemid 36305590)
103. Johnson BN, Berger AK, Cortese GP, LaVoie MJ (2012) The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci U S A 109:6283-6288
104. Ekholm-Reed S, Goldberg MS, Schlossmacher MG, Reed SI (2013) Parkin-dependent degradation of the f-box protein fbw7beta promotes neuronal survival in response to oxidative stress by stabilizing mcl-1. Mol Cell Biol 33:3627-3643
105. Chen D, Gao F, Li B, Wang HF, Xu YX, Zhu CQ, Wang GH (2010) Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. J Biol Chem 285:38214-38223
106. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS, Jensen PH (2002) Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem 277:15303-15308 (Pubitemid 34967791)
107. Kahns S, Kalai M, Jakobsen LD, Clark BF, Vandenabeele P, Jensen PH (2003) Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J Biol Chem 278:23376-23380 (Pubitemid 36830153)
108. Lee K, Lee MH, Kang YW, Rhee KJ, Kim TU, Kim YS (2012) Parkin induces apoptotic cell death in TNF-alpha-treated cervical cancer cells. BMB Rep 45:526-531
109. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
110. Periquet M, Corti O, Jacquier S, Brice A (2005) Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 95:1259-1276 (Pubitemid 41779252)
111. Davison EJ, Pennington K, Hung CC, Peng JH, Rafiq R, Ostareck-Lederer A, Ostareck DH, Ardley HC, Banks RE, Robinson PA (2009) Proteomic analysis of increased parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics 9:4284-4297
112. Xun Z, Kaufman TC, Clemmer DE (2009) Stable isotope labeling and label-free proteomics of Drosophila parkin null mutants. J Proteome Res 8:4500-4510
113. Greene JC, Whitworth AJ, Andrews LA, Parker TJ, Pallanck LJ (2005) Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 14:799-811 (Pubitemid 40403276)
114. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131:2183-2194 (Pubitemid 38702049)
115. Saini N, Oelhafen S, Hua H, Georgiev O, Schaffner W, Bueler H (2010) Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways. Neurobiol Dis 40:82-92
116. Yu F, Zhou J (2008) Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress. Neurosci Lett 440:4-8
117. Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B, Jenner P (2002) Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 277:28572-28577 (Pubitemid 41079284)
118. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V et al (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Gene Dev 25:460-470
119. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107:8788-8793
120. LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG (2007) The effects of oxidative stress on parkin and other E3 ligases. J Neurochem 103:2354-2368 (Pubitemid 350173558)
121. Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J (2003) Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 278:47199-47208 (Pubitemid 37452306)
122. Meng F, Yao D, Shi Y, Kabakoff J, Wu W, Reicher J, Ma Y, Moosmann B, Masliah E, Lipton SA et al (2011) Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol Neurodegener 6:34
123. Wong ES, Tan JM, Wang C, Zhang Z, Tay SP, Zaiden N, Ko HS, Dawson VL, Dawson TM, Lim KL (2007) Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J Biol Chem 282:12310-12318 (Pubitemid 47100679)
124. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T et al (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8:834-842 (Pubitemid 44151586)
125. Cha GH, Kim S, Park J, Lee E, Kim M, Lee SB, Kim JM, Chung J, Cho KS (2005) Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci U S A 102:10345-10350 (Pubitemid 41023373)
126. Hwang S, Kim D, Choi G, An SW, Hong YK, Suh YS, Lee MJ, Cho KS (2010) Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila. Mol Cells 29:575-580
127. Henn IH, Bouman L, Schlehe JS, Schlierf A, Schramm JE, Wegener E, Nakaso K, Culmsee C, Berninger B, Krappmann D et al (2007) Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 27:1868-1878
128. Rawal N, Corti O, Sacchetti P, Ardilla-Osorio H, Sehat B, Brice A, Arenas E (2009) Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Bioph Res Co 388:473-478
129. Ren Y, Jiang H, Ma D, Nakaso K, Feng J (2011) Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum Mol Genet 20:1074-1083
130. 2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 336:1306-1310